| 摘要 |
<p>Charybdotoxin or the active fraction thereof, are useful in the treatment of conditions, eg. ischemia, hypoxia or contusion caused by calcium activated potassium efflux from cells. Pharmaceutical compositions are disclosed. The active fraction, identified as MR117, is claimed, together with the preparation thereof by enzyme digestion of charybdotoxin followed by isolation performed by chromatography.</p> |
